To include your compound in the COVID-19 Resource Center, submit it here.

Puma sinks after CHMP expresses doubts on neratinib

Puma Biotechnology Inc. (NASDAQ:PBYI) slipped $26.20 (29%) to $64.70 on Wednesday after it said EMA's CHMP communicated a "negative trend vote" for its

Read the full 233 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE